BARCELONA, Spain, Sept. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT ® ...
In August, the FDA approved another first-line treatment option for patients with EGFR-mutant non-small cell lung cancer (NSCLC): the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib ...
On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor ...
Please provide your email address to receive an email when new articles are posted on . Patients who received subcutaneous amivantamab-vmjw every 4 weeks plus lazertinib had similar outcomes as those ...
Bispecific antibodies (BsAbs) enhance NSCLC treatment by targeting dual antigens, improving efficacy, and overcoming resistance compared to conventional monoclonal antibodies. Amivantamab and ...
Risk of non-breast cancer–related mortality in breast cancer and dependence on disease characteristics, treatment, and survival duration. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Bilateral Mediastinal Lymphadenectomy Is Associated With Potential Survival Advantages in Patients With Stage I Non–Small Cell Lung Cancer Who Undergo Lung Resection Lung cancer remains a leading ...
Subcutaneous amivantamab is approved in Europe in combination with LAZCLUZE® for the first-line treatment of adult patients with advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results